NASDAQ: PGENPrecigen Inc Stock Ownership - Who owns Precigen?
Insider buying vs selling
Have Precigen Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Phil Tennant | Chief Commercial Officer | 2026-05-28 | 30,272 | $4.36 | $131.99kSell |
| Donald P. Lehr | Chief Legal Officer | 2026-05-28 | 29,131 | $4.36 | $127.01kSell |
| Rutul R. Shah | Chief Operating Officer | 2026-05-28 | 42,703 | $4.36 | $186.19kSell |
| Harry Thomasian Jr. | Chief Financial Officer | 2026-05-28 | 41,884 | $4.36 | $182.61kSell |
| Helen Sabzevari | President and CEO | 2026-05-28 | 119,250 | $4.36 | $519.93kSell |
| Randal J. Kirk | Director | 2026-03-30 | 370,847 | $3.30 | $1.22MSell |
| Randal J. Kirk | Director | 2026-03-30 | 152,063 | $3.30 | $501.81kSell |
| Randal J. Kirk | Director | 2026-03-30 | 50,797 | $3.30 | $167.63kSell |
| Randal J. Kirk | Director | 2026-03-30 | 2,334,420 | $3.30 | $7.70MSell |
| Randal J. Kirk | Director | 2026-03-30 | 23,789 | $3.30 | $78.50kSell |
PGEN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when PGEN insiders and whales buy or sell their stock.
PGEN Shareholders
What type of owners hold Precigen Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Randal J. Kirk | 72.52% | 258,555,888 | $923.04M | Insider |
| Trading Sa Ares | 5.79% | 20,647,152 | $73.71M | Insider |
| Patient Capital Management LLC | 5.00% | 17,817,387 | $63.61M | Institution |
| Blackrock Inc | 4.27% | 15,223,191 | $54.35M | Institution |
| State Street Corp | 3.05% | 10,890,124 | $38.88M | Institution |
| Vanguard Capital Management LLC | 2.01% | 7,148,996 | $25.52M | Institution |
| Diametric Capital LP | 1.91% | 6,801,788 | $24.28M | Institution |
| Point72 Asset Management LP | 1.86% | 6,644,361 | $23.72M | Institution |
| Tang Capital Management LLC | 1.80% | 6,417,500 | $22.91M | Institution |
| Geode Capital Management LLC | 1.29% | 4,613,429 | $16.47M | Institution |
PGEN vs Biotech Stocks
Precigen Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.